Showing 5881-5890 of 9808 results for "".
- Sun Pharma’s WINLEVI for Acne Now Availablehttps://practicaldermatology.com/news/sun-pharmas-winlevi-for-acne-now-available/2460974/WINLEVI (clascoterone) cream 1% is now available the US, according to Sun Pharmaceutical Industries Limited. A first-in-class topical androgen receptor inhibitor, WINLEVI was approved by FDA in August 2020 for the topical treatment of acne vulgaris in patients 12 yea
- Dupixent Reduces Itch, Clears Skin in Prurigo Nodularis Phase 3 Trialhttps://practicaldermatology.com/news/dupixent-reduces-itch-clears-skin-in-prurigo-nodularis-phase-3-trial/2460969/Data from a pivotal Phase 3 trial show that Dupixent® (dupilumab) reduced itch and led to higher rates of skin clearance than placebo among adults with uncontrolled prurigo nodularis. In the Phase 3 PRIME2 trial, 37 percent of Dupixent
- Crown Aesthetics Launches SkinPen Precision Ambassador Programhttps://practicaldermatology.com/news/crown-aesthetics-launches-skinpen-precision-ambassador-program/2460968/Crown Aesthetics announced the launch of their SkinPen Ambassador Program in conjunction with National Microneedling Day. The SkinPen Ambassador Program presents current SkinPen providers with the opportunity to showcase their practice success and to share valuable insights and SkinPen
- Resilia Pharmaceuticals Obtains Marketing License for Solace Eczema Creamhttps://practicaldermatology.com/news/resilia-pharmaceuticals-obtains-marketing-license-for-solace-eczema-cream/2460967/Resilia Pharmaceuticals, Inc. will market and sell Solace™ Eczema Cream, a medical device, as an OTC product in the US, after signing a license agreement with Pelle Ventures, LLC. Financial terms of the transaction were not disclosed. Previously only avai
- Castle Creek Biosciences Awarded FDA Orphan Products Development Grant to Support Phase 3 Study of FCX-007 Investigational Gene Therapy for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/castle-creek-biosciences-awarded-fda-orphan-products-development-grant-to-support-phase-3-study-of-fcx-007-investigational-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa/2460966/The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development awarded Castle Creek Biosciences a $1.825 million research grant to support the Phase 3 development program of the investigational gene therapy FCX-007 for treatment of recessive dystrophic epide
- Can Applying an Electric Field to the Skin Cure Fibrosis?https://practicaldermatology.com/news/can-applying-an-electric-field-to-the-skin-cure-fibrosis/2460965/Applying an electric field to the skin could cure skin fibrosis by reducing overly high collagen levels, a new study suggests. Published in the Journal of Investigative Dermatology, the results open new therapeutic perspectives for the topical treatment of skin fibrosis charact
- Mount Sinai Awarded $4 Million Grant to Launch Skin Biology and Diseases Resource-based Centerhttps://practicaldermatology.com/news/mount-sinai-awarded-4-million-grant-to-launch-skin-biology-and-diseases-resource-based-center/2460963/The Icahn School of Medicine at Mount Sinai is establishing a Skin Biology and Diseases Resource-based Center (SBDRC), funded by a $4 million, five-year P30 grant from the National Institutes of Health and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- EWG: UVA Protection of Most Sunscreens Just 25 Percent of Touted SPFhttps://practicaldermatology.com/news/ewg-most-sunscreens-comprise-just-25-percent-of-touted-spf/2460962/Many sunscreens offer just a quarter of their stated SPF protection against ultraviolet A rays, a new Environmental Working Group (EWG)
- Upsher-Smith Introduces Isotretinoin Capsules in UShttps://practicaldermatology.com/news/upsher-smith-introduces-isotretinoin-capsules-in-us/2460960/Isotretinoin capsules AB2-rated to the branded product Absorica® (isotretinoin) are now available in 10mg, 20mg, 30mg, and 40mg strengths from
- Study: Laser Plus Topical Steroids May Improve VLS Symptomshttps://practicaldermatology.com/news/study-laser-plus-topical-steroids-may-improve-vls-symptoms/2460959/Adding fractional CO2 laser treatments to topical steroids may maximize treatment outcomes in refractory vulvar lichen sclerosus (VLS), according to a new study in Lasers in Surgery and